SCHEMBL25979412

SCHEMBL25979412

Cc1cccc(CC(C)c2ccccn2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
RECQL P46063 1/20 0.45
ALDH1A1 P00352 3/20 0.44
HPGD P15428 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
HTT P42858 2/20 0.40
KMT2A Q03164 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
PSMD14 O00487 1/20 0.40
LMNA P02545 1/20 0.40
CYP1A2 P05177 1/20 0.40
AGTR1 P30556 1/20 0.40
OPRK1 P41145 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
TSHR P16473 1/20 0.39
TAAR1 Q96RJ0 3/20 0.39
CYP11B1 P15538 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3249970 0.83 MAOA (0.50) CYP2D6ALDH1A1NPSR1HTTKDM4E
SCHEMBL18950253 0.83 SLC6A2 (0.42) CYP2D6ALDH1A1HPGDNPSR1HTT
SCHEMBL20385424 0.82 ESR1 (0.46) CYP2D6ALDH1A1NPSR1KDM4ETSHR
SCHEMBL20385505 0.82 ESR1 (0.46) CYP2D6ALDH1A1NPSR1KDM4ETSHR
SCHEMBL23661902 0.82 CYP11B1 (0.44) CYP1A2TSHRCYP11B1CYP11B2
SCHEMBL24337020 0.80 ESR1 (0.36) CYP2D6CYP2C9ALDH1A1KMT2AKDM4E
SCHEMBL19117511 0.76 TAAR1 (0.37) CYP2C19CYP2D6ALDH1A1HPGDNPSR1
SCHEMBL19924441 0.75 TSHR (0.36) CYP2D6NPSR1HTTKDM4ETSHR
SCHEMBL14032656 0.74 ESR1 (0.66) ALDH1A1KDM4ECYP1A2TSHRTAAR1
SCHEMBL2563917 0.74 PNMT (0.62) TAAR1SLC6A2MAOASLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250060-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250060-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 CYP2C19 4839/4885CYP2D6 4347/4885CYP2C9 4838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.